Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled studyAuthor Response

Editors' Note: Commenting on “Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study,” Galduroz and colleagues argue that the negative findings of the study may be related to a confusion of concepts such as impulsivity, compulsivity, and craving. Furthermore, Liang and colleagues suggest that some impulse control disorders may be more responsive to naltrexone than others. Authors Weintraub et al. respond. Sethi and Strowd discuss the challenges of modern electronic medicine. —Chafic Karam, MD, and Robert C. Griggs, MD Papay et al.1 reported no significant effects of naltrexone in comparison to placebo to treat impulse control disorders (ICD) in Parkinson disease (PD). We suggest the results may be partially explained by problems with the outcome measures. The questionnaire used in the study …